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Background: The purposes of this study were to investigate the prevalence of psychotropic 
(hypnotic, antidepressant, and anxiolytic) drug use among adolescents aged 15–16 years during 
the period 2006–2010 according to gender and subcategories of psychotropics, and to study 
psychotropic drug use over the period 2007–2010 among incident users in 2007.
Methods: This was a one-year prevalence and follow-up study based on information retrieved 
from the nationwide Norwegian prescription database for the period 2006–2010. The study 
population consisted of adolescents aged 15–16 years who had filled at least one prescription for 
a psychotropic drug in the study period. The main outcome measures were filling of hypnotic, 
antidepressant, and/or anxiolytic drug prescriptions.
Results: Overall use of psychotropic drugs increased from 13.9 to 21.5 per 1000 among boys 
and from 19.7 to 24.7 per 1000 among girls during the 2006 –2010 period. Hypnotic drugs, and 
melatonin in particular, accounted for most of the increase. For melatonin, the annual median 
amount dispensed was 180 defined daily doses through the period until 2010, at which time it 
decreased to 90 defined daily doses. In total, 16.4% of all incident psychotropic drug users in 
2007 were still having prescriptions dispensed in 2010.
Conclusion: This study shows an increase in hypnotic drugs dispensed for adolescents in 
 Norway, mainly attributable to the increasing use of melatonin. The amount of melatonin 
dispensed indicates more than sporadic use over longer periods, despite melatonin only being 
licensed in Norway for use in insomnia for individuals aged 55 years or older.
Keywords: psychotropic drugs, hypnotics, sedatives, antidepressive agents, antianxiety agents, 
adolescents, prescription database, defined daily dose, long-term use
Introduction
International studies in recent decades have shown an increase in psychotropic drug use 
among adolescents. In the US, this use has increased by 2–3-fold in the past 20 years.1,2 
In Norway, and other Nordic countries, the overall use of psychotropic drugs by 
 adolescents seems to be low, except for Iceland, where it is reported to be high.3,4
In 2005, Skurtveit et al3 found a relatively low self-reported use of psychotropic 
drugs in a Norwegian urban adolescent population, being about 4% among girls and 
boys. However, between 2004 and 2009, there was a trend of increasing hypnotic drug 
use by Norwegian adolescents.5 Furthermore, incident use seemed to be high among 
those aged 15–16 years in 2000–2003, and 15% had filled at least one prescription 
for one of the study drugs 1–9 years later.6
The appropriateness of psychotropic drug use among adolescents is  controversial. 
As early as 1994, Simeon et al7 described knowledge about psychotropic drug use 
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in this group as developing slowly because of lack of 
research, ethical issues, regulations, and opposition to use 
of psychotropic medication in adolescents. Today, studies 
claim that too many psychotropic drugs are used off-label 
in adolescents.8–10
Variations in psychotropic drug use between young popu-
lations have been observed in previous studies, which may 
reflect variations in culture, guidelines, health service organi-
zation, economic and diagnostic criteria, and study design.8,10 
Several earlier studies exploring psychotropic drug use are 
based on self-reported information, insurance or reimburse-
ment data, and community or localized pharmacy dispensing 
data.4,10–12 In this context, the nationwide  Norwegian prescrip-
tion database constitutes a valid data source for conducting 
pharmacoepidemiological studies at an individual level in an 
unselected adolescent population.13
Overall, studies on psychotropic drug use among ado-
lescents are scarce and do not give any detailed information 
on patterns of use over time by age, gender, or subcategory 
of psychotropic medication. The purposes of this study 
were to investigate the one-year prevalence of  psychotropic 
 (hypnotic, antidepressant, anxiolytic) drug use among adoles-
cents aged 15–16 years during 2006–2010 related to gender 
and subcategories of psychotropic medication, and to study 
use of psychotropic drugs in the period 2007–2010 among 
incident psychotropic drug users in 2007.
Materials and methods
This study is based on data from the Norwegian prescription 
database during 2006–2010.13 Since January 1, 2004, all 
pharmacies in Norway have been legally obliged to send in 
electronic data on all prescriptions to the Norwegian  Institute 
of Public Health. The Norwegian prescription database con-
tains information on all individuals living outside institutions 
who have received drug prescriptions dispensed at pharmacies. 
All prescriptions, whether reimbursed or not, are stored in the 
database. The drugs are categorized according to the Anatomi-
cal Therapeutic Chemical (ATC) classification system.13,14 The 
data collected for this study included patient unique identifying 
number (encrypted), gender, age, date of dispensing, and drug 
information (ATC code, defined daily dose).
Quantities of dispensed drugs are measured in terms 
of the number of defined daily doses. The defined daily 
dose is the assumed average maintenance dose per day 
for a drug used among adults for its main indication.14 
Psychotropic subcategories in this study included antide-
pressant,  hypnotic, and anxiolytic drugs. Table 1 show all 
Table 1 Psychotropic substances registered in Norway in 2011, 
and included in the study with assigned defined daily doses
ATC code Name DDD
N05C hypnotics and sedatives
N05CA barbiturates, plain
 N05CA04 Barbital 500 mg
N05CD benzodiazepine derivatives
 N05CD02 Nitrazepam 5 mg
 N05CD03 Flunitrazepam 1 mg
 N05CD08 Midazolam 15 mg
N05CF benzodiazepine-related drugs (Z hypnotics)
 N05CF01 Zopiclone 7.5 mg
 N05CF02 Zolpidem 10 mg
N05CH melatonin receptor agonists
 N05CH01 Melatonin 2 mg
N05CM other hypnotics and sedatives
 N05CM02 Clomethiazole 150 mg
 N05CM05 Scopolamine 0.9 mg
R06 antihistamines for systemic use
R06 AD phenothiazine derivatives
 R06AD01 Alimemazine 30 mg
 R06AD02 Promethazine 25 mg
N06A antidepressants
N06 AA nonselective monoamine reuptake inhibitors
 N06AA04 Clomipramine 100 mg
 N06AA06 Trimipramine 150 mg
 N06AA09 Amitriptyline 75 mg
 N06AA10 Nortriptyline 30 mg
 N06AA12 Doxepin 100 mg
N06 AB selective serotonin reuptake inhibitors
 N06AB03 Fluoxetine 120 mg
 N06AB04 Citalopram 20 mg
 N06AB05 Paroxetine 20 mg
 N06AB06 Sertraline 50 mg
 N06AB08 Fluvoxamine 100 mg
 N06AB10 Escitalopram 10 mg
N06 AG monoamine oxidase A inhibitor
 N06AG02 Moclobemide 300 mg
N06 AX other antidepressants
 N06AX03 Mianserin 60 mg
 N06AX11 Mirtazapine 30 mg
 N06AX12 Bupropion 300 mg
 N06AX16 Venlafaxine 100 mg
 N06AX18 Reboxetine 8 mg
 N06AX21 Duloxetine 60 mg
N05B anxiolytics
N05BA benzodiazepine derivatives
 N05BA01 Diazepam 10 mg
 N05BA04 Oksazepam 50 mg
 N05BA12 Alprazolam 1 mg
N05BB diphenylmethane derivatives
 N05BB01 Hydroxyzine 75 mg
N05BE azaspirodecanedione derivatives
 N05BE01 Buspirone 30 mg
Abbreviations: ATC code, Anatomical Therapeutic Chemical classification system; 
DDD, defined daily doses.
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 psychotropic substances included in this study with assigned 
defined daily doses.
Phenothiazine-derivative systemic antihistamines 
(ATC code R06AD) have long been used for childhood 
insomnia in Norway, and constituted the second most com-
monly  prescribed hypnotic drug among adolescents aged 
0–17 years in Norway in 2008. For this reason, phenothiazine 
 prescriptions were included in the analysis and are referred 
to as “hypnotic drugs”, together with Z drugs and benzodi-
azepines (ATC code N05C).
The study population consisted of adolescents aged 
15–16 years in 2006, 2008, and 2010, who had filled at 
least one prescription for any of the psychotropic drug 
 subcategories. The age of 15–16 years constitutes a special 
time of growth, with many social, mental and physical 
changes taking place. The Norwegian prescription database 
covers the entire nation, which renders it possible to study 
patterns of use in narrow age bands.
Analytical approaches
The one-year prevalence of psychotropic drug use in 2006, 
2008, and 2010, overall, and in psychotropic drug subgroups, 
was estimated by identifying individuals who had at least 
one prescription filled in that year per 1000 inhabitants. The 
denominator is based on the total number of Norwegian 
inhabitants aged 15–16 years in the actual year registered 
by  Statistics Norway.15 The annual amounts of psychotro-
pic drugs used are presented as median and interquartile 
ranges.
Among incident drug users in 2007, the proportion of con-
tinued use throughout the period was calculated. An incident 
user in 2007 was defined as having at least one prescription 
filled in 2007 and none during 2004–2006. Long-term use 
was defined as filling of at least one prescription each year in 
the period 2007–2010 by a 2007 incident drug user. Analyses 
were performed using SPSS 17.0 for Windows (SPSS Inc, 
Chicago, IL).
Table 2 Norwegian prescription database showing one-year prevalence of use of psychotropic drugs by boys and girls aged 15–16 years
 2006 2008 2010
Boys (n) 
65,481
Girls (n) 
62,090
Boys (n) 
64,928
Girls (n) 
61,354
Boys (n) 
65,956
Girls (n) 
62,056
n /1000 n /1000 n /1000 n /1000 n /1000 n /1000
Any psychotropic below 909 13.9 1221 19.7 1151 17.7 1373 22.4 1418 21.5 1531 24.7
Hypnotics (ATC code N05C + R06AD) 612  9.3 726 11.7 877 13.5 942 15.4 1144 17.3 1077 17.4
Antidepressants (ATC code N06A) 282  4.3 487  7.8 322  5.0 503  8.2 344  5.2 559  9.0
Anxiolytics (ATC code N05B) 152  2.3 232  3.7 150  2.3 225  3.7 151  2.3 209  3.4
Abbreviation: ATC code, The Anatomical Therapeutic Chemical classification system.
Results
One-year prevalence of psychotropic 
drug use versus subcategory and gender
Overall, one-year prevalence of psychotropic drug use 
increased among adolescents in the period 2006–2010 from 
2130 (16.7 per 1000) in 2006 to 2949 (23.0 per 1000) in 
2010. Among the boys, one-year prevalence increased during 
this period from 13.9 to 21.5 per 1000 inhabitants. Among 
the girls, the corresponding figures were 19.7 and 24.7 per 
1000 (Table 2).
During the same period, the one-year prevalence of 
hypnotic drugs increased from 1338 (10.5 per 1000) to 2221 
(17.3 per 1000), and its prevalence increased in both genders. 
Among boys, it nearly doubled from 9.3 to 17.3 per 1000 and 
among girls from 11.7 to 17.4 per 1000 (Table 2). Melatonin 
accounted for most of this increase (Figure 1A and B).
Antidepressants were the second most often used psy-
chotropic drugs in both genders. In 2006, 769 (6.0 per 1000) 
adolescents used antidepressants and 903 (7.0 per 1000) used 
them in 2010 (Table 2). On average, girls showed higher 
use of antidepressants than boys (Figure 1C and D). Use of 
anxiolytics was relatively low and stable for both genders 
throughout the study period (Table 2).
Annual amount of psychotropic drugs 
dispensed
The median annual amount of hypnotic drugs dispensed for 
boys was stable during 2006 and 2008 at 180 defined daily 
doses, but decreased to 90 defined daily doses in 2010. 
Hypnotic drug dispensing for girls showed the same trend, 
but was dispensed at lower levels (Table 3).
Among the hypnotic drugs, melatonin receptor agonists 
(ATC code N05CH) were prescribed most often for both 
boys and girls, with an annual median amount dispensed of 
180 defined daily doses through the period until 2010, when 
it decreased to 90 defined daily doses (Table 3).
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Figure 1 (A and B) Norwegian prescription database showing one-year prevalence 
of hypnotic drug use by Norwegian boys and girls aged 15–16 years between 2004 
and 2010. (C and D) One-year prevalence of antidepressant drug use by Norwegian 
boys and girls aged 15–16 years between 2004 and 2010.
Among the boys, the median annual amount of antide-
pressant drugs dispensed was relatively stable at 177–182 
defined daily doses in the study period. Corresponding figures 
for girls were lower (Table 3). The substances used most 
often were the selective serotonin reuptake inhibitors (ATC 
code N06AB), being used almost equally by both genders 
throughout 2006–2010 (Figure 1C and D). Anxiolytic drugs 
had the lowest median annual amount dispensed, and were 
rarely used for adolescents (Table 3).
Follow-up of psychotropic drug  
use (2007–2010)
Among incident users of psychotropic drugs in 2007, 16.4% 
(234 of 1429) filled at least one annual psychotropic drug 
prescription in the period 2007–2010 (Table 4). Among those 
having an antidepressant dispensed in 2007, almost a quarter 
were still being dispensed antidepressants in 2010. Among 
incident users of hypnotic drugs in 2007, 8.4% still filled 
hypnotic drug prescriptions in 2010 (Table 4).
Discussion
Overall, this nationwide study showed an increase in 
 hypnotic drug use among adolescents between 2006 and 
2010. Hypnotic drugs constituted 75% of all psychotropic 
drugs dispensed, and increased by 40% during the period, 
whereas use of anxiolytics and antidepressants was stable 
in this period. Other studies have shown similar trends in 
use of these psychotropic drugs over time, corresponding 
well with the results of our study.5,12,16,17 The most striking 
observation in the current study was the increase in use 
of melatonin, which accounted for most of the increase in 
hypnotic drug use. Melatonin is a hormone which helps 
to regulate other hormones in the body and maintain the 
body’s circadian rhythm.18 The annual amount of melatonin 
dispensed between 2007 and 2010 indicates more than 
 sporadic use among  adolescents. Fifty percent of the boys 
using melatonin received an annual amount correspond-
ing to one defined daily dose every second day or more in 
2006–2008, decreasing to every fourth day in 2010, and 25% 
filled melatonin prescriptions corresponding to use of more 
than one defined daily dose every day. Obviously, melatonin 
has acquired a major role in the treatment of adolescent sleep 
problems in Norway, parallel to observations in an earlier 
study.5 Treatment of young people with melatonin has been 
controversial, especially in the prepubertal years, because it 
may affect reproduction.19 Attention has been drawn to the 
effects of medication related to age, gender, and physical and 
psychological development. Using drugs during puberty may 
have permanent effects on the developing brain, especially 
developmental psychopathology. 19,20 In Norway, melatonin 
is indicated as monotherapy for short-term treatment of pri-
mary insomnia characterized by poor quality of sleep among 
patients aged 55 years and older.5 In spite of this, recent 
studies conclude that melatonin for treatment of adolescent 
insomnia is safe.21,22
Antidepressants were the most common psychotropic drug 
used by adolescents in the long-term. After 4 years, almost 
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Table 3 Norwegian prescription database showing annual amount of psychotropic drug use in terms of defined daily dose among boys 
and girls aged 15–16 years
2006 2008 2010
Median (IQR) Median (IQR) Median (IQR)
Boys Girls Boys Girls Boys Girls
Hypnotic drugs (ATC code  
N05C + R06AD)
180 (90–450) 90 (16–237) 180 (90–450) 90 (21–270) 90 (21–270) 47 (21–180)
Benzodiazepine derivatives 7 (3–38) 20 (10–27) 10 (3–20) 20 (3–70) 20 (10–163) 20 (10–40)
Benzodiazepine-related drugs 13 (7–30) 10 (7–27) 15 (7–30) 13 (7–30) 20 (10–30) 13 (7–30)
Melatonin receptor agonists 180 (90–540) 180 (90–450) 180 (90–540) 180 (90–360) 90 (42–357) 90 (21–270)
Phenothiazine derivatives 17 (8–46) 8 (8–33) 12 (8–33) 8 (8–33) 17 (8–33) 8 (8–29)
Antidepressants (ATC code N05A) 177 (84–350) 140 (56–302) 200 (90–392) 130 (58–300) 182 (90–322) 139 (58–302)
Nonselective monoamine reuptake  
inhibitors
13 (13–40) 13 (13–30) 33 (13–67) 17 (13–27) 17 (13–48) 17 (13–33)
Selective serotonin reuptake inhibitors 200 (100–392) 196 (98–379) 234 (100–399) 188 (100–336) 198 (100–360) 196 (98–364)
Other antidepressants 45 (15–102–75) 45 (15–87) 45 (15–123) 30 (15–84) 60 (30–160) 30 (15–100)
Anxiolytics (ATC code N05B) 8 (3–17) 8 (4–13) 13 (5–27) 13 (5–26) 13 (10–25) 13 (5–27)
Benzodiazepine derivatives 10 (5–13) 5 (4–10) 8 (5–12) 5 (5–10) 20 (5–25) 8 (5–13)
Diphenylmethane derivatives 8 (3–19) 8 (3–17) 13 (13–33) 13 (13–33) 30 (13–33) 13 (13–33)
Azaspirodecanedione derivatives 48 (47) 22 (6–218) 133 (133–133) 67 (50–83) 42 (8–142)
Abbreviations: IQR, interquartile range; ATC code, Anatomical Therapeutic Chemical classification system.
Table 4 Norwegian prescription database showing long-term use* (%) of psychotropic drugs (2007–2010) among all Norwegian 
incident users aged 15–16 years in 2007
2007 2008 2009 2010
n % n % n % n %
Psychotropic category 1429 100 600 42.0 345 24.1 234 16.4
Hypnotic drugs (ATC code N05C + R06AD) 1126 100 345 30.6 166 14.7 95  8.4
Antidepressants (ATC code N06A) 504 100 284 56.3 166 32.9 115 22.8
Anxiolytics (ATC code N05B) 312 100 38 12.2 15  4.8 6  1.9
Note: *Retrieval of at least one prescription of a psychotropic drug each year in the period 2007–2010 among incident users in 2007 ATC code. 
Abbreviation: ATC code, Anatomical Therapeutic Chemical classification system.
a quarter of incident users in 2007 still filled a  prescription 
for antidepressants in 2010. This may be expected because 
treatment with antidepressants is recommended for some 
time. Girls were more often prescribed antidepressants than 
boys, possibly due to the fact that they are more likely to 
present with depressive or anxiety disorders and ask their 
physicians for help.23
Off-label use of antidepressants among adolescents is 
described as frequent, with most dispensing being unlicensed 
for this age group, but there are variations from country to 
country.12 The safety of antidepressants in adolescents is 
debatable, not only because of the increased risk of suicide,24 
but also in view of the effects on neurological and behavioral 
development.25,26 The current study shows relatively stable 
prescription rates for antidepressants among adolescents aged 
15–16 years in the 2006–2010 periods. In 2003, the European 
and Norwegian health authorities issued a series of warnings 
against use of antidepressants by adolescents, especially 
selective serotonin reuptake inhibitors and  venlafaxine.27 
As a consequence, the prescription rate decreased in the 
period 2004–2006.27 From our observations for 2010, it 
appears that the warnings have had some effect on prescrib-
ing in the long term.
Methodological strengths and limitations
An important strength of this study is its use of a comprehen-
sive national prescription register, which eliminates errors 
in measurement of psychotropic drug use due to inadequate 
recall by respondents. Another advantage of using register-
based information is that it circumvents the common problem 
of psychotropic drug use being underreported.28,29 However, 
lack of information on adherence is always an issue when 
reporting prescription data for drug use. We do not know 
how many of the drugs purchased were actually taken. 
In some countries, misuse has become a problem among 
adolescents. Furthermore, sharing prescription drugs, and 
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getting  prescription drugs from a relative or friend seems to 
be a trend.30 This may have led to underestimation or over-
estimation of drug use in this study. Further, adolescents in 
hospitals and institutions are not registered in the Norwegian 
prescription database, so were not taken into account in our 
study. Another limitation is that we do not have any informa-
tion on the indications for use of the study drugs.
Conclusion
This study shows an increase in hypnotic drug dispensing 
for adolescents in Norway in the period 2006–2010, mainly 
attributable to increasing use of melatonin. Furthermore, the 
amount of melatonin dispensed indicates more than sporadic 
use over longer periods, despite melatonin only being licensed 
in Norway for insomnia in patients 55 years and older. Use of 
antidepressants was highest among girls, although dispensing 
for both genders was stable throughout the study period.
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